Novo Nordisk gets fresh Goldman target, shares extend recent gains
28.06.2026 - 14:33:09 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 14:32.
Novo Nordisk (DK0060534915) remains a focal name on Nasdaq Copenhagen as analysts refine their views on the obesity leader. Goldman Sachs this week raised its price target on the stock to 310 Danish kroner while reiterating a Neutral stance, according to MarketScreener’s summary of the note.
What Goldman Sachs signals
Goldman Sachs’ latest update nudges its target from 305 to 310 kroner, reflecting a modest adjustment rather than a change in fundamental view. The house keeps Novo Nordisk at Neutral, underscoring a balanced risk-reward after a strong run in the shares.
The target sits slightly below the current cash price in Copenhagen, where Novo Nordisk closed at 317.95 kroner on June 26, 2026, up 0.73 percent on the day. The shares trading above the Goldman target highlight how market pricing has moved ahead of some research assumptions.
How the consensus picture looks
Consensus data compiled by MarketScreener shows a mix of Buy and Hold recommendations on Novo Nordisk, with recent moves including a downgrade from Morningstar to Hold from Buy while maintaining a 343-kroner target price. This divergence between a Neutral from Goldman and a higher target from Morningstar points to differing views on valuation stretch versus long-term growth.
The stock’s inclusion in key European benchmarks such as the OMX Copenhagen 25 and the Stoxx Europe 50 keeps it firmly on the radar of global portfolio managers. In New York, the NVO American Depositary Receipts closed at 48.01 dollars on June 26, 2026, up 0.78 percent, with TrendSpider noting a roughly 5 percent gain over the past 30 days.
All news and analysis on the Novo Nordisk shares
Further coverage on Novo Nordisk, including earnings, analyst updates and price data, is available in the dedicated topic section.
The business behind the stock
Novo Nordisk generates the bulk of its revenue from diabetes and obesity care, anchored by GLP-1 based therapies such as semaglutide, marketed for obesity under the Wegovy brand. The company has expanded capacity and geographic reach for these products as demand from patients and payers has increased.
Where the shares trade today
The Novo Nordisk shares (DK0060534915) last closed on June 26, 2026, at 317.95 Danish kroner on Nasdaq Copenhagen. This pricing places the company among the highest-valued pharma names in the Nordic region.
Key data on the Novo Nordisk shares
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- WKN: A3EU6F
- Ticker: NOVO B (Copenhagen), NVO (NYSE ADR)
- Trading venue: Nasdaq Copenhagen, NYSE ADR
- Price (as of 2026-06-26, 17:30): 317.95 DKK
- Market cap: approximately 2,100 billion DKK (as of 2026-06-26)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: OMX Copenhagen 25, Stoxx Europe 50, Stoxx Europe 600
- Next earnings date: 2026-08-05
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
